Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Amyloid-β (Aβ) and tau proteins currently represent the two most promising targets to treat
Alzheimer's disease. The most extensively developed method to treat the pathologic forms of …

The development of therapeutic antibodies has evolved over the past decade into a
mainstay of therapeutic options for patients with autoimmune and inflammatory diseases …

CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRPα interaction and enables
macrophage-mediated killing of tumor cells in hematological cancer cell lines. In this first …

The immune response depends on the binding of opsonized antigens to cellular Fc
receptors and the subsequent initiation of various cellular effector functions of the immune …

Chimeric antigen receptors (CAR) combine an antigen-binding domain with a CD3-ζ
signaling motif to redirect T-cell specificity to clinically important targets. First-generation …

Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …

Nanoscience and Nanotechnology have found their way into the fields of Biotechnology and
Medicine. Nanoparticles by themselves offer specific physicochemical properties that they …

2004-11-10 Assigned to XENCOR, INC. reassignment XENCOR, INC. ASSIGNMENT OF
ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DANG, WEI …

The success of adoptive therapy using chimeric antigen receptor (CAR)–expressing T cells
partly depends on optimal CAR design. CARs frequently incorporate a spacer/linker region …